181 related articles for article (PubMed ID: 15346837)
1. Ischemic heart disease: metabolic approaches to management.
Pauly DF; Pepine CJ
Clin Cardiol; 2004 Aug; 27(8):439-41. PubMed ID: 15346837
[TBL] [Abstract][Full Text] [Related]
2. Role of metabolically active drugs in the management of ischemic heart disease.
Schofield RS; Hill JA
Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulators for chronic cardiac ischemia.
Parang P; Singh B; Arora R
J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
[TBL] [Abstract][Full Text] [Related]
4. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
César LA; Gowdak LH; Mansur AP
Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648
[TBL] [Abstract][Full Text] [Related]
5. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H; Zarain-Herzberg A; Maisch B
Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
[TBL] [Abstract][Full Text] [Related]
6. Metabolic management of ischaemic heart disease.
Chierchia SL; Fragasso G
Eur Heart J; 1993 Nov; 14 Suppl G():2-5. PubMed ID: 7904560
[TBL] [Abstract][Full Text] [Related]
7. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
Rizzon P; Iliceto S; Marangelli V
Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732
[No Abstract] [Full Text] [Related]
8. Metabolic support for the heart: complementary therapy for heart failure?
Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
[TBL] [Abstract][Full Text] [Related]
9. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Lee L; Horowitz J; Frenneaux M
Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
[TBL] [Abstract][Full Text] [Related]
10. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities.
Yao Z; Gong S; Guan T; Li Y; Wu X; Sun H
Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1218-22. PubMed ID: 19881270
[TBL] [Abstract][Full Text] [Related]
12. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley WC; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
[No Abstract] [Full Text] [Related]
13. Ranolazine and the myocardial demand-supply balance.
Klocke FJ
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1310-2. PubMed ID: 19909935
[No Abstract] [Full Text] [Related]
14. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.
McCormack JG; Barr RL; Wolff AA; Lopaschuk GD
Circulation; 1996 Jan; 93(1):135-42. PubMed ID: 8616920
[TBL] [Abstract][Full Text] [Related]
15. Metabolic modulation and optimization of energy consumption in heart failure.
Ferrari R; Cicchitelli G; Merli E; Andreadou I; Guardigli G
Med Clin North Am; 2003 Mar; 87(2):493-507, xii-xiii. PubMed ID: 12693736
[TBL] [Abstract][Full Text] [Related]
16. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic application of myocardial cytoprotection].
Ribeiro C
Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
[No Abstract] [Full Text] [Related]
18. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate.
Matsumura H; Hara A; Hashizume H; Maruyama K; Abiko Y
Jpn J Pharmacol; 1998 May; 77(1):31-9. PubMed ID: 9639058
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis.
Folmes CD; Clanachan AS; Lopaschuk GD
Curr Atheroscler Rep; 2005 Feb; 7(1):63-70. PubMed ID: 15683605
[TBL] [Abstract][Full Text] [Related]
20. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents.
Grynberg A
Curr Pharm Des; 2005; 11(4):489-509. PubMed ID: 15725067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
